Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNTVUK)

Drug Name

TS01 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Stroke	8B20	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Complement C1s component (C1S)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cinryze	DMVIKJZ	Hereditary angioedema	4A00.14	Approved	[3]
Sutimlimab	DMY7WH1	Cold type autoimmune haemolytic anemia	3A20.1	Approved	[4]
SAR445088	DMQV3IM	Chronic inflammatory demyelinating polyneuropathy	8C01.3	Phase 2	[5]
SHP616	DMO0CA8	Neuromyelitis optica	8A43	Phase 1	[6]
ANX005	DMAESIY	Neurodegenerative disorder	8A20-8A23	Phase 1	[7]
TNT009	DMSKF29	Bullous pemphigoid	EB41.0	Phase 1	[6]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[8]
PMID16460935C28	DM8BKI4	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037017)
2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
4	Antibodies to watch in 2020. MAbs. Jan-Dec 2020;12(1):1703531.
5	First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor. Clin Transl Sci. 2023 Apr;16(4):673-685.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9	A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2200-4.